EVALUATION OF PROPRANOLOL-GLUCAGON TEST

1977 ◽  
Vol 86 (2) ◽  
pp. 243-250 ◽  
Author(s):  
Y. Okada ◽  
K. Watanabe ◽  
T. Takeuchi ◽  
T. Hata ◽  
H. Mikam ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Body Weight ◽  
False Negative ◽  
Human Growth ◽  
Maximum Level ◽  
Normal Children ◽  
Provocative Test ◽  
Glucagon Test ◽  
Control Subjects ◽  
Stimulation Of

ABSTRACT A propranolol-glucagon test was evaluated in 24 control normal children, 21 pituitary dwarfs, 15 patients with constitutional short stature, 2 with chromosome aberration and 4 with miscellaneous diseases. The dose of glucagon enough for the stimulation of human growth hormone (HGH) secretion is more than 20 μg/kg of body weight. During the test in the control subjects the serum HGH level increased from 2.3 ± 1.2 ng/ml to a maximum level of 30.0 ± 15.1 ng/ml, when 10 mg propranolol, regardless of body weight and 30 μg glucagon per kg of body weight are given. The dose of propranolol administered ranged from 0.2 to 1.0 mg/kg of body weight in normal children studied. Serum 11-OHCS also increased significantly from 14.5 ± 11.2 μg/100 ml to 30.1 ± 15.5 μg/100 ml (P <0.01). There was no difference in the maximum level of urinary total catecholamines in propranolol-glucagon test between 7 pituitary dwarfs and 7 control subjects. The mechanism of HGH response to propranolol-glucagon administration is unknown, but propranolol-glucagon administration is a sensitive and reliable provocative test for HGH secretion, since false negative responses of HGH are not observed in patients with non-pituitary disease.

Drs. Shanis and Moshang Reply

PEDIATRICS ◽  
1977 ◽  
Vol 60 (5) ◽  
pp. 778-779
Author(s):  
Bonnie S. Shanis ◽  
Thomas Moshang
Keyword(s):  
Growth Hormone ◽  
False Negative ◽  
Normal Children ◽  
Provocative Test ◽  
Short Children ◽  
The One

We appreciate the interest and attention of Dr. Pombo et al. to the use of propranolol and exercise as a provocative test of growth hormone (GH) release. Since publication of our article, we have studied an additional 24 normal short children and three Gil-deficient children. Twenty-two of the 24 normal children had GH levels greater than 10 ng/ml. Therefore, among the total 56 normal children evaluated, the incidence of false-negative responses was 3.6%, slightly lower than the one in 15 reported by Maclaren et al. and the one in 17 reported by the above authors. See table in the PDF file

scholarly journals Sp1 can displace GHF-1 from its distal binding site and stimulate transcription from the growth hormone gene promoter.

1990 ◽  
Vol 10 (4) ◽  
pp. 1811-1814 ◽  
Author(s):  
F P Lemaigre ◽  
D A Lafontaine ◽  
S J Courtois ◽  
S M Durviaux ◽  
G G Rousseau
Keyword(s):  
Growth Hormone ◽  
Promoter Activity ◽  
Gene Promoter ◽  
Human Growth ◽  
Growth Hormone Gene ◽  
Dnase I Footprinting ◽  
Kinetics Of ◽  
Distal Site ◽  
Human Growth Hormone Gene ◽  
Stimulation Of

DNase I footprinting experiments showed that binding activities of Sp1 and of GHF-1 to its distal site on the human growth hormone gene promoter are mutually exclusive. The kinetics of GHF-1 binding were indicative of positive cooperativity. The Sp1 site did not affect promoter activity in cell-free transcription. Still, Sp1 could compensate partially for the decreased stimulation of transcription seen at low GHF-1 concentrations.

Human and rat growth hormones enhance guanylate cyclase activity

1981 ◽  
Vol 240 (2) ◽  
pp. E79-E82
Author(s):  
D. L. Vesely
Keyword(s):  
Growth Hormone ◽  
Guanylate Cyclase ◽  
Soluble Guanylate Cyclase ◽  
Human Growth ◽  
Growth Hormones ◽  
Cyclase Activity ◽  
Kidney Cortex ◽  
Guanylate Cyclase Activity ◽  
Rat Growth ◽  
Stimulation Of

The objective of this investigation was to determine whether physiological levels of growth hormone have part of their mechanism of action through stimulation of guanylate cyclase (EC 4.6.1.2.). Rat and human growth hormones enhanced the activity of soluble guanylate cyclase two- to fourfold in rat gracilis anticus skeletal muscle, liver, lung, heart, pancreas, and kidney cortex at a concentration of 10 nM. Dose-response relationships revealed that more than half-maximal stimulation of guanylate cyclase activity was seen at a concentration as low as 10 nM and nonstimulation of guanylate cyclase activity was seen when the concentration was decreased to 1 nM. Maximal enhancement was seen at 100 nM of growth hormone, and there was no further enhancement when the concentration was increased to the micromolar or millimolar range. Thus, the data in this investigation indicate that at concentrations at which growth hormone is known to cause its growth-promoting effects, growth hormone does cause an enhancement of the activity of the guanylate cyclase-cyclic GMP system.

THE EFFECT OF HUMAN GROWTH HORMONE ON SUBCUTANEOUS FAT THICKNESS IN HYPOSOMATOTROPHIC AND PANHYPOPITUITARY DWARFS

1967 ◽  
Vol 39 (2) ◽  
pp. 263-275 ◽  
Author(s):  
J. M. TANNER ◽  
R. H. WHITEHOUSE
Keyword(s):  
Growth Hormone ◽  
Human Growth Hormone ◽  
Subcutaneous Fat ◽  
Human Growth ◽  
Skinfold Thickness ◽  
Normal Children ◽  
Subcutaneous Fat Thickness ◽  
Fat Thickness ◽  
Metabolic Action ◽  
Very High

SUMMARY The changes in skinfold thickness over the triceps and under the scapula were measured by the same observer every 3 months in 21 children before and during treatment with human growth hormone (HGH). Eleven hyposomatotrophic dwarfs showed a trebling of their rate of height growth during the first 3 months of treatment, and in all, the skinfolds, measuring mainly the amount of subcutaneous fat, decreased during the first 3 months of treatment. In some subjects in this group the skinfold values tended to rise gradually again as treatment progressed. All except two of these children had very high initial skinfold values; the average percentile was above the 75th before treatment, and at the 50th after 3 months of treatment. Four children, thought to have the same diagnosis, showed little or no height acceleration; they showed also little or no response in skinfold thickness; three of them were initially lean. Two small normal children and one child with gonadal dysgenesis responded neither in height nor in skinfolds. Three children with operated craniopharyngiomas responded well in height, but only one responded unequivocally in skinfolds. We think the response in dwarfed children represents a true metabolic action of HGH, since there was clinical evidence of a rise and not of a diminution in appetite. The possible implications of these results in the understanding of the physiological events underlying the normal curve of growth in fat in children, particularly at infancy and adolescence, are outlined.

Sign in / Sign up

Export Citation Format

Share Document